DAMORA THERAPEUTICS, INC. Investments and Cash
DAMORA THERAPEUTICS, INC. (DMRA) had Investments and Cash of $257.60 million as of 2025-12-31, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:InvestmentsAndCash · last filed 2026-08-10
- 2025-12-31: Investments and Cash $257.60M.
- 2024-12-31: Investments and Cash $14.20M.
- 2024-03-31: Investments and Cash $27.20M.
- 2023-12-31: Investments and Cash $33.20M.
| Period end | Investments and Cash | Investments and Cash as first filed |
|---|---|---|
| 2025-12-31 | $257.60M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $14.20M 10-K · filed 2026-03-19 | |
| 2024-03-31 | $27.20M 10-Q · filed 2024-04-29 | |
| 2023-12-31 | $33.20M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $44.20M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $52.10M 10-Q · filed 2023-07-31 | |
| 2023-03-31 | $57.20M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $66.10M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $75.90M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $85.90M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $101.80M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $109.20M 10-K · filed 2023-03-09 | $109.20K 10-K · filed 2022-02-17 |
| 2021-09-30 | $127.60M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $137.70M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $148.90M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |